Report reveals economic and racial disparity in access to weight-loss drugs for low-income and minority patients in the US.

A report by The Washington Post reveals an economic and racial disparity in access to weight-loss drugs, particularly among low-income neighborhoods and Black and Hispanic patients in the US. Despite these groups being more likely to suffer from obesity and type 2 diabetes, they are less likely to be prescribed weight-loss drugs like Ozempic and Mounjaro due to financial barriers and lack of insurance. Researchers suggest that addressing social determinants of health, such as cultural factors and biased beliefs from doctors, is crucial in achieving equal access to these medications.

August 19, 2024
8 Articles

Further Reading